Baxa Corporation Introduces DoseEdge(TM) TPN Pharmacy Workflow Management Software for TPN Compounding

ENGLEWOOD, Colo., April 7 /PRNewswire/ -- Baxa Corporation, a leading provider of medical devices and systems that automate pharmacy operations and increase patient safety, today announced the release of DoseEdge TPN, the industry's first product for completely managing the workflow for automated TPN production. When used with Abacus® TPN calculation software and the ExactaMix™ 2400 Compounder, DoseEdge TPN provides automated support for the entire TPN dose preparation, documentation and inspection process.

"Automated TPN compounding is recognized as one of the most successful pharmacy technologies – adding safety, process control, accuracy and speed to what had been a labor-intensive and error-prone process of compounding TPN doses by hand," notes Larry Gibson, Product Manager. "The Baxa DoseEdge Pharmacy Workflow Manager has supported the safe preparation of more than 1.5 million preparations. DoseEdge TPN leverages this experience – improving the TPN compounding process with complete workflow support and many patient safety enhancements."

After automated TPN compounding is complete, DoseEdge TPN can help catch and prevent errors in the workflow and processes. The software also includes extensive new safety functionality for manual additions. Its pharmacist inspection capabilities, complete dose status tracking – displaying current status and status transitions – and long-term storage of detailed information permit better management and audit of the TPN dose preparation process. Additionally, DoseEdge TPN provides all of the benefits of the company's leading DoseEdge Pharmacy Workflow Manager – including barcode verification of ingredients, automated volume calculations and photographic evidence of proper measurement and injection.

In a prior announcement, Baxa launched significant upgrades to the DoseEdge Pharmacy Workflow Manager. This Baxa DoseEdge Pharmacy Workflow Manager upgrade extends DoseEdge capabilities beyond IV preparation to encompass liquid doses such as oral medications.

Product Availability

DoseEdge TPN and the DoseEdge Pharmacy Workflow Manager are available immediately. For information about how DoseEdge supports lean pharmacy initiatives, download a free technical paper at www.baxa.com/doseedge.  For more information about DoseEdge Products, visit www.baxa.com/PharmacyProducts/DoseManagement.

About Baxa Corporation

Baxa, a customer-focused medical device company, provides innovative, solution-based technologies for medication handling and delivery.  Its systems and devices promote the safe and efficient preparation, handling, packaging, and administration of medications.  Key products include the Abacus® Order Entry and Calculation Software, the DoseEdge™ Pharmacy Workflow Manager (formerly IntelliFlow™), ExactaMed® Oral Dispensers, ExactaMix™ Automated Compounding Devices, MicroFuse® Syringe Infusers, Repeater™ Pharmacy Pumps, the PadLock®  Set Saver and the Rapid-Fill™ Automated Syringe Filler; used worldwide in hospitals and healthcare facilities.  Its subsidiary FHT, Inc. produces the IntelliFill i.v. ® automation.  Privately held, Baxa Corporation has subsidiaries and sales offices in Florida, Canada and the United Kingdom; direct representation in Austria, Belgium, Denmark, Finland, France, Germany, Italy, Luxembourg, The Netherlands and Switzerland; and distribution partners worldwide.  Further information is available at www.baxa.com.

Contact:

Marian Robinson, Vice President, Marketing

Baxa Corporation:  800.567.2292 ext. 2157 or 303.617.2157

Email:  [email protected]


Perrin McCormick or Dawn Sullivan

Hart-Boillot: 781-893-0053

Email: [email protected]



SOURCE Baxa Corporation

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.